Substantiation of the choice of components for a combined drug used for the treatment of type 2 diabetes mellitus [Text] / K. N. Toraiev [et al.] // Вісн. фармації. - 2017. - № 1. - P25-31 Рубрики: Бенфотиамин MeSH-головна: ЛЕКАРСТВА КОМБИНИРОВАННЫЕ -- DRUG COMBINATIONS МЕТФОРМИН -- METFORMIN ДИАБЕТ САХАРНЫЙ, ТИП 2 -- DIABETES MELLITUS, TYPE 2 (лекарственная терапия) МЕТА-АНАЛИЗ -- META-ANALYSIS ГИПОГЛИКЕМИЧЕСКИЕ СРЕДСТВА -- HYPOGLYCEMIC AGENTS АНТИОКСИДАНТЫ -- ANTIOXIDANTS Анотація: Diabetes mellitus (DM) is one of the most common non-communicable diseases in the world. As evidenced by the UN resolution, DM is recognized as one of the most threatening diseases in the world. At present there are more than 382 million people with DM. In the EU almost 4-6 % of the population suffers from type 2 diabetes mellitus (DM 2). It should be noted that this disease occurs with an extremely high risk of complications, which lead to disability, morbidity and mortality of patients in this category. Aim. To substantiate the choice of components for introduction of a combined drug used for the treatment of DM 2 Дод.точки доступу: Toraiev, K. N. Nemchenko, A. S. Tsubanova, N. A. Bezchasniuk, O. M. Yevsieieva, L. V. Вільних прим. немає